Skip to main content
Fig. 1 | Allergy, Asthma & Clinical Immunology

Fig. 1

From: Long-term mepolizumab treatment reduces relapse rates in super-responders with eosinophilic granulomatosis with polyangiitis

Fig. 1

Protocol and follow-up for patients with EGPA who were treated with mepolizumab for at least 3 years. The initial group consisted of 71 patients with EGPA who had visited Hiratsuka City Hospital from April 2018 to March 2022. We excluded six patients on initial treatment and 22 who had achieved remission with conventional treatment. We then analyzed the data on the remaining 25 patients treated with mepolizumab who were followed up for at least 3 years. We analyzed the clinical characteristics of responders and super-responders separately

Back to article page

Allergy, Asthma & Clinical Immunology

ISSN: 1710-1492

Contact us